Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panfoxol for URTI-related Otolaryngological Diseases
NCT05806086Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of OM-85 in allergic rhinitis (AR), chronic rhinosinusitis (CRS), secretory otitis media (SOM) and 1 more (3 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Therapeutic effective rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
OM-85
03
Conditions
allergic rhinitis (AR)chronic rhinosinusitis (CRS)secretory otitis media (SOM)tonsillar hypertrophy
Beyond the preview
Go deeper on NCT05806086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806086.